In comparison with control group for liver cirrhosis, emricasan treatment showed no substantial impact on INR (SMD=0.12; 95% CI=-0.13 to 0.37; P=0.36; Figure 4), total bilirubin (SMD=-0.27; 95% CI=-0.56 to 0.01; P=0.06; Figure 5), serum albumin (SMD=0; 95% CI=-0.25 to 0.25; P=1.00; Figure 6) or adverse events (OR=1.35; 95% CI=0.56 to 3.24; P=0.50; Figure 7). This evidence concerns the gene ALB and cirrhosis of liver.